About US
Contact us
-
Curie-Cancer and DNA Therapeutics partner to combat cancerCurie-Cancer and French biopharmaceutical firm DNA Therapeutics have renewed their partnership to provide a new class of therapeutic cancer products to patients, including those resistant to conventio2014/3/11
-
Endo obtains FDA approval for Aveed injectable replacement therapy for hypogonadismEndo Pharmaceuticals has received approval from the US Food and Drug Administration (FDA) for its new prescription medicine Aveed (testosterone undecanoate) injection to treat adult men with hypogonad2014/3/11
-
Tracon and Santen partner to develop TRC105 in ophthalmologyUS-based Tracon Pharmaceuticals has entered into an exclusive agreement with Japan-based Santen Pharmaceutical for the development and global commercialisation of its anti-endoglin antibodies, includi2014/3/10
-
Eisai and Biogen partner to develop new treatments for Alzheimer'sJapanese pharmaceutical firm Eisai has entered into a collaboration with US-based Biogen Idec for the development and commercialisation of Eisai's two clinical candidates E2609 and BAN2401 for treatin2014/3/10
-
Forest Laboratories submits NDA to FDA for combination drug to treat Alzheimer's diseaseUS-based Forest Laboratories has submitted a new drug application (NDA) to the US Food and Drug Administration (FDA) for a fixed-dose combination (FDC) of memantine HCl extended release (ER) and donep2014/3/7
-
AstraZeneca obtains FDA approval for Bydureon Pen to treat type 2 diabetesAstraZeneca has received approval from the US Food and Drug Administration (FDA) for its Bydureon Pen (exenatide extended-release for injectable suspension) 2mg as an adjunct to diet and exercise to i2014/3/7
-
Bayer seeks Japanese approval for VEGF Trap-Eye to treat diabetic macular edemaBayer HealthCare's Japanese subsidiary Bayer Yakuhin has submitted a marketing authorisation application to Japan's Ministry of Health, Labour and Welfare (MHLW) for vascular endothelial growth factor2014/3/6
-
Eisai and Biogen Idec Collaborate to Develop and Commercial​ize Alzheimer'​s Disease TreatmentsEisai Co., Ltd and Biogen Idechave entered into a collaboration to develop and commercialise two of Eisai’s clinical candidates for Alzheimer’s disease (AD), E2609 and BAN2401. The agreement also prov2014/3/6
-
GW Pharma obtains FDA orphan status for Epidiolex for treatment of Lennox syndromeBritish biopharmaceutical firm GW Pharmaceuticals has received orphan drug designation from the US Food and Drug Administration (FDA) for its Epidiolex as a treatment for Lennox-Gastaut syndrome (LGS)2014/3/5
-
Ignyta files IND application with FDA for tumour drug RXDX-101Ignyta has filed an investigational new drug application (IND) with the US Food and Drug Administration (FDA) for its RXDX-101, an oral tyrosine kinase inhibitor targeting solid tumour indications. T2014/3/5